There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Esperion (ESPR – Research Report), Beam Therapeutics (BEAM – Research Report) and Opko Health (OPK – Research Report) with bullish sentiments.
Esperion (ESPR)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00. The company’s shares closed last Tuesday at $2.90.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
Esperion has an analyst consensus of Strong Buy, with a price target consensus of $8.78, a 232.6% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Beam Therapeutics (BEAM)
In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Beam Therapeutics, with a price target of $56.00. The company’s shares closed last Tuesday at $45.07.
According to TipRanks.com, Semenkow is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Beam Therapeutics with a $52.27 average price target, which is a 31.5% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
Opko Health (OPK)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Opko Health, with a price target of $3.00. The company’s shares closed last Tuesday at $1.05, close to its 52-week low of $0.85.
According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Opko Health has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ESPR:
- Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
- Esperion sees 2024 operating expenses $225M-$245M
- Esperion reports Q4 EPS (50c), consensus (48c)
- ESPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
